P2RY1 and thrombotic disease: It is still necessary to explore an oral antiplatelet agent targeting P2Y1 and/or P2Y12 for the treatment of thrombotic diseases to overcome the drawbacks of these clinical drugs and achieve a fast onset of action with less bleeding risk [42].